News | December 13, 2023
Pfizer receives regulatory approvals to complete the acquisition of Seagen
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
